Trial reportJournal of neuro-oncology2026
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.
Trial report in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02628067 (A Clinical Trial of Pembrolizumab), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)
Who cites it
2 citing papers in PubMed.
- Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.Cancers · 2024Review
- The co-inhibitory immune checkpoint proteins B7-H1(PD-L1) and B7-H4 in high grade glioma: From bench to bedside.Translational oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecurrent gliomas have limited treatment options and dismal outcomes. We report the efficacy and safety of the anti–programmed cell death protein-1 antibody pembrolizumab in participants with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) recurrent glioma in KEYNOTE-158.
methodsThe phase 2, multicohort KEYNOTE-158 study (NCT02628067) is evaluating pembrolizumab monotherapy in participants with advanced rare cancers. This analysis focused on participants with recurrent glioma from cohort K where eligible participants were ≥18 years old with MSI-H/dMMR tumors and measurable disease per RECIST v1.1. Participants received pembrolizumab 200 mg every 3 weeks for up to 35 cycles. The primary endpoint was objective response rate (ORR) per RECIST v1.1 by independent central radiologic review.
resultsTwenty-one participants with recurrent glioma were enrolled. Median (range) follow-up was 50.0 (15.4‒65.5) months. Best overall responses were partial response (PR; n = 1, 5%), stable disease (SD; n = 3, 14%), and disease progression (n = 16, 76%); 1 participant (5%) had no postbaseline assessment. ORR (95% CI) was 5% (0.1%‒24%). Of 4 participants with SD or better, median (range) duration of their response was 27.8 (0.0+‒27.8) months. The participant with PR had progression-free survival (PFS) of 29.2 months and overall survival (OS) of 32.7 months; among the 3 participants with SD, PFS ranged from 3.3–23.2 months and OS ranged from 9.1–23.2 months. Treatment-related AEs occurred in 7/21 participants (33%; grade 3‒4, n = 1 [5%]).
conclusionPembrolizumab monotherapy demonstrated antitumor activity in a small subset of participants and manageable safety in MSI-H/dMMR recurrent glioma.
trial registrationClinicalTrials.gov, NCT02628067; Registered, December 9, 2015.
Indexed as
Identifiers
41920388What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.